Page last updated: 2024-12-05

lucanthone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lucanthone, also known as Miracil D, is a synthetic antiparasitic drug used to treat schistosomiasis. It was first synthesized in 1948 and is a derivative of the dye, acriflavine. Lucanthone acts by interfering with the metabolism of the parasite, Schistosoma mansoni, leading to its death. However, it has several side effects, including nausea, vomiting, and dizziness, and its use is now limited due to the availability of safer and more effective treatments. Research continues to investigate the potential of lucanthone in treating other parasitic diseases and exploring its mechanism of action. Lucanthone's importance lies in its historical significance as one of the first effective treatments for schistosomiasis and its potential for future applications in parasitic disease control.'

Lucanthone: One of the SCHISTOSOMICIDES, it has been replaced largely by HYCANTHONE and more recently PRAZIQUANTEL. (From Martindale The Extrapharmacopoeia, 30th ed., p46) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lucanthone : A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10180
CHEMBL ID279014
CHEBI ID51052
SCHEMBL ID9156
MeSH IDM0012715

Synonyms (46)

Synonym
NCIMECH_000830
1-[[2-(diethylamino)ethyl]amino]-4-methylthioxanthone
1-{[2-(diethylamino)ethyl]amino}-4-methyl-9h-thioxanthen-9-one
1-(2-diethylaminoethylamino)-4-methyl-thioxanthen-9-one
NSC14574 ,
lucantona
CHEBI:51052 ,
lucanthonum
lucanthone
479-50-5
DB04967
1-{[2-(diethylamino)ethyl]amino}-4-methylthioxanthen-9-one
1-diethylaminoethylethylamino-4-methyl-thioxanthenone
1-((2-(diethylamino)ethyl)amino)-4-methylthioxanthen-9-one
lucanthon
einecs 207-532-4
thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-
brn 0312369
ccris 1106
lucanthone [inn:ban]
ai3-16160
lucantona [inn-spanish]
lucanthonum [inn-latin]
9h-thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-
NCI60_000988
CHEMBL279014
5-18-11-00503 (beilstein handbook reference)
fc6d57000m ,
unii-fc6d57000m
CCG-35817
S6471
lucanthone [mi]
1-((2-(diethylamino)ethyl)amino)-4-methyl-9h-thioxanthen-9-one
lucanthone [inn]
1-(2-diethylaminoethylamino)-4-methylthiaxanthone
SCHEMBL9156
DTXSID6023230
AKOS028110687
bdbm50030282
9h-thioxanthen-9-one, 1-[[2-(diethylamino)ethyl]amino]-4-methyl-
CS-6665
HY-B2098
Q6696022
BS-49111
1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one
F88010

Research Excerpts

Overview

Lucanthone is an antitumour drug used as an adjuvant in radiation therapy.

ExcerptReferenceRelevance
"Lucanthone is an antitumour drug used as an adjuvant in radiation therapy. "( Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone.
Bailly, C; Dassonneville, L, 1999
)
1.97

Actions

Lucanthone seems to enhance the radiosensitivity of certain cell types but not of the tumor tested. Lucanthone did not inhibit repair of X-ray-induced DNA single-strand breaks.

ExcerptReferenceRelevance
"Lucanthone did not inhibit repair of X-ray-induced DNA single-strand breaks."( Effects of lucanthone on the sedimentation properties of DNA from HeLa cells.
Bases, R; Blake, C; Leifer, A; Neubort, S; Rozycki, H, 1977
)
1.37
"Thus lucanthone seems to enhance the radiosensitivity of certain cell types but not of the tumor tested."( Radiosensitization and radioprotection studies on Ehrlich ascites tumor. II. Experimental trial of lucanthone to enhance the radiosensitivity of the tumor.
Roa, KR, 1977
)
0.93

Dosage Studied

The effects of Astiban, Lucanthone, Hycanthone and Niridazole on autophagic activities in the gastrodermis of Schistosoma mansoni were determined in vivo. The application of Lucanth one increased the number of damaged fetuses and led to various degrees of sensitization depending on the mouse strain and dosage used.

ExcerptRelevanceReference
" The application of Lucanthone increased the number of damaged fetuses and led to various degrees of sensitization depending on the mouse strain and dosage used."( Radiation damage in mouse embryos exposed to 1 rad x-rays or negative pions.
Fritz-Niggli, H; Michel, C, 1977
)
0.58
"The effects of Astiban, Lucanthone, Hycanthone and Niridazole on autophagic activities in the gastrodermis of Schistosoma mansoni were determined in vivo, using different dosage levels and dosage times."( Schistosoma mansoni: an in vivo study of drug-induced autophagy in the gastrodermis.
Clarkson, J; Erasmus, DA, 1984
)
0.57
"THIS REVIEW OF THE PUBLISHED WORK ON THE TREATMENT OF BILHARZIASIS WITH LUCANTHONE HYDROCHLORIDE DRAWS ATTENTION TO THE INCONCLUSIVE NATURE OF MANY OF THE TRIALS CARRIED OUT SO FAR: either the dosage was inadequate or the patients were not followed up for a sufficient length of time."( Lucanthone hydrochloride; a review.
BLAIR, DM, 1958
)
1.91
" The shoulders of radiation dose-response curves were enhanced by pretreatment of cells with Hsp70 and, importantly, were reduced when cells were transfected with ribonucleic acid designed to silence Hsp70."( Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70.
Bases, R, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
schistosomicide drugDrugs that used to treat infestations by flukes (trematodes) of the genus Schistosoma.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
photosensitizing agentA chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.
EC 5.99.1.2 (DNA topoisomerase) inhibitorA topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
adjuvantAny pharmacological or immunological agent that modifies the effect of other agents such as drugs or vaccines while having few if any direct effects when given by itself.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
thioxanthenesThioxanthene and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency26.21230.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency26.21230.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)IC50 (µMol)5.00000.05502.967710.0000AID1167344; AID1370990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)Kd0.08900.00090.02540.0890AID1370992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
telomere maintenanceDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repair, gap-fillingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA catabolic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA recombinationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of apoptotic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of mRNA stabilityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cell redox homeostasisDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
negative regulation of DNA-templated transcriptionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
telomere maintenance via base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
damaged DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded telomeric DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription coactivator activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription corepressor activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA-DNA hybrid ribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase I activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
uracil DNA N-glycosylase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
protein bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphoric diester hydrolase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5'-DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA exodeoxyribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5' exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
oxidoreductase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
site-specific endodeoxyribonuclease activity, specific for altered baseDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
chromatin DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
metal ion bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
class II DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase activity, acting on 3'-phosphoglycolate-terminated DNA strandsDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(abasic site) bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA 3'-5' DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
chromosome, telomeric regionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleolusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
mitochondrionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endoplasmic reticulumDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
centrosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
ribosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nuclear speckDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
perinuclear region of cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1203061Cytotoxicity against human HCC1937 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1203057Cytotoxicity against human HCC1954 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1203058Cytotoxicity against human BT474 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID153753In vivo antitumor activity against NCI P-388 lymphocytic leukemia in mice at a dose of 100 mg/kg1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Ring-hydroxylated analogues of lucanthone as antitumor agents.
AID1370990Inhibition of full length human APE1 expressed in Escherichia coli BL21/DE3 assessed as inhibition of incision of depurinated supercoiled pUC18 plasmid DNA after 15 mins2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
AID213153Apparent association constant (Kapp) for binding to purified calf thymus DNA1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Ring-hydroxylated analogues of lucanthone as antitumor agents.
AID1370992Binding affinity to full length human APE1 expressed in Escherichia coli BL21/DE32017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
AID153884In vivo antitumor activity against P-388 lymphocytic leukemia in mice treated with a dose of 100 mg/kg1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Analogues of hycanthone and lucanthone as antitumor agents.
AID1203056Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1203062Cytotoxicity against human BT20 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1203059Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1203060Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1167344Inhibition of human APE1 after 25 mins by fluorescence assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (280)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990257 (91.79)18.7374
1990's5 (1.79)18.2507
2000's4 (1.43)29.6817
2010's10 (3.57)24.3611
2020's4 (1.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.29 (24.57)
Research Supply Index5.73 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (3.03%)5.53%
Reviews16 (5.39%)6.00%
Case Studies2 (0.67%)4.05%
Observational0 (0.00%)0.25%
Other270 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme [NCT01587144]Phase 218 participants (Actual)Interventional2012-06-19Terminated(stopped due to Sponsor's decision)
Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer [NCT02014545]Phase 20 participants (Actual)Interventional2016-01-31Withdrawn(stopped due to Pending resolution of study drug issues)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]